论文部分内容阅读
利用放免技术测定血清TGF α与TNF α水平 ,观察其在卵巢癌、卵巢良性肿瘤患者及正常对照组 (各 30例 )中变化情况。结果卵巢癌组TGF α增高与正常对照及卵巢良性肿瘤组差别显著 (P <0 0 5 ) ;30例卵巢癌组中 2 8例TNF α增高与正常对照组及卵巢良性肿瘤组差别显著 (P <0 0 5 ) ,2例低于同组水平 ;后两组TGF α与TNF α差别不显著 (P >0 0 5 )。结果表明TGF α、TNF α增高与卵巢癌相关 ,卵巢癌患者TGF α增高而TNF α降低提示预后较差。
Serum levels of TGFα and TNFα were measured by radioimmunoassay, and their changes in ovarian cancer, benign ovarian tumor and normal control group (30 cases each) were observed. Results The increase of TGF-α in ovarian cancer group was significantly different from that in normal control group and benign ovarian tumor group (P <0.05). In 30 cases of ovarian cancer group, the increase of TNFα in 28 cases was significantly different from that in normal control group and benign ovarian tumor group (P <0 0 5), 2 cases were lower than the same group level; the latter two groups had no significant difference (P> 0.05). The results showed that elevated TGF α, TNF α and ovarian cancer, ovarian cancer patients with elevated TGF α and TNF α decreased the prognosis is poor.